FCA
AXSM icon

FinTrust Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

FinTrust Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed – – 1213
2022
Q1 		$0 Hold
10
– – ﹤0.01% 1218
2021
Q4 		$0 Buy
+10
New +$368 ﹤0.01% 1186

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

FinTrust Capital Advisors's AXSM Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2022, closing a stake of 10 shares.

FinTrust Capital Advisors first reported a position in AXSM in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 174 funds tracked by Wall St. Rank hold AXSM as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Axsome Therapeutics position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 10 Axsome Therapeutics shares in Q2 2022.
  • FinTrust Capital Advisors first reported a position in Axsome Therapeutics in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Axsome Therapeutics position peaked at $0 in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.